Latest Headlines

Online Exclusive

CMS Expands Access to CAR T-Cell Therapies Nationwide

The Centers for Medicare and Medicaid Services (CMS) will now provide “consistent and predictable” nationwide access to chimeric antigen receptor (CAR) T-cell therapies, according...

Doctors Rally to Support Disabled Indian Medical School Applicants in Legal...

Doctors and medical groups from the U.S., U.K., and Australia expressed their opposition to a recent decision from the Medical Council of India (MCI)...

Cover Story

Predatory Publishing: The Dark Side of the Open-Access Movement

In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker side of scientific publishing: predatory publishing. This segment of the OA publishing movement is characterized by publishers that “unprofessionally exploit” the gold OA model (in which the final version of a manuscript is made freely available on publication), primarily for profit, according to Jeffrey Beall, MSLS, one of the most vigilant watchdogs of predatory publishing, and operator of the website Scholarly Open Access. Sometimes called “vanity presses,” these entities publish practically any materials that come their way, as long as authors are willing to pay a submission and publication fee. Critics – and they are legion...

Clinical News

Latest Videos

Pulling Back the Curtain: Saad Z. Usmani, MD

In more from our interview with Saad Z. Usmani, MD, he shares life lessons learned throughout his career.

Pulling Back the Curtain: Anna Schuh, MD, PhD

In more from our interview with Anna Schuh, MD, PhD, she shares her experiences volunteering with hematology patients in Tanzania.

Robert Kreitman: Delayed Versus Concurrent Rituximab in Hairy Cell Leukemia

Robert Kreitman, MD, shares results from a new study suggesting patients with hairy cell leukemia should receive rituximab concurrently with frontline cladribine.

Tibor Kovacsovics: CX-01 Associated With High Response Rates in Older Patients...

Tibor Kovacsovics, MD, discusses CX-01, a heparin derivative that induced high response rates in older patients newly diagnosed with acute myeloid leukemia.

On Location

On location

Daratumumab Combination Induces High Response Rates in AL Amyloidosis

In one-year follow-up data from the phase III ANDROMEDA trial, the combination of subcutaneous daratumumab...
On location

Erythropoietin Increases Hemoglobin and Reticulocyte Counts in Patients with Treatment-Refractory AIHA

In patients with autoimmune hemolytic anemia (AIHA) unresponsive to ongoing and/or prior therapies, treatment with...
On location

Single-Agent Ibrutinib Improves Survival and Prolongs Time to Next Treatment in Early-Stage CLL

In the double-blind, randomized CLL12 trial, patients with treatment-naïve, early-stage chronic lymphocytic leukemia (CLL) who...
On location

AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma

In updated results from the first-in-human study of the bispecific T-cell engager (BITE) AMG 420,...
On location

Exploring New Settings for Tagraxofusp: CMML and Myelofibrosis

In late 2018, the U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of...
On location

Luteinizing Hormone Suppression Improves Post-Chemotherapy Hematopoietic Recovery in Patients With Leukemia

Treatment of leukemia with intensive chemotherapy increases patients’ risk of infection and bleeding due to...
Advertisement

Sign Up for our enewsletter!

Subscribe to our newsletter to receive the latest news, updates and online exclusive content.

8,802FollowersFollow
10,255SubscribersSubscribe

Pregnancy History and Sex of Red Cell Donors Does Not Increase Mortality Risk for...

Previous research has suggested that receipt of a red blood cell (RBC) transfusion from a female donor who has ever been pregnant increases mortality...
Sickle cell anemia

Voxelotor Increases Hemoglobin, Decreases Hemolysis in Patients With Sickle Cell Disease

A report from the phase III HOPE trial found that once-daily voxelotor led to greater increases in hemoglobin (Hb) levels and larger reductions in...

Can a Patient’s Breath Detect Post-Transplant Gastrointestinal Graft-Versus-Host Disease?

Analyzing the volatile organic compounds (VOCs) expelled in the breath can help clinicians detect and monitor gastrointestinal graft-versus-host disease (GI GVHD) in patients who...

Bluebird Bio Wins European Approval for Beta Thalassemia Gene Therapy

Bluebird Bio’s one-time gene therapy, Zynteglo, has been cleared by E.U. regulators for the treatment of beta thalassemia in patients aged 12 and older....
WIB_icon

Short, Aggressive Antibiotic Therapy Inhibits Lymphocyte Proliferation in CTCL

According to a study published in Blood, patients with advanced-stage cutaneous T cell lymphoma (CTCL) a short, yet aggressive, antibiotic regimen inhibited disease activity...